PFS data of platinib

Pralsetinib is an oral small molecule multi-target tyrosine kinase inhibitor that mainly targets the Ret (recombinant human primary retinal ganglioside receptor tyrosine kinase) signaling pathway and is used to treat various cancer types with RET gene mutations, including non-small cell lung cancer (NSCLC) and thyroid cancer.

Platinib's progression-free survival (PFS) data in the treatment of RET-mutant non-small cell lung cancer and thyroid cancer show a certain therapeutic effect. For patients with RET-mutant non-small cell lung cancer, the PFS data of platinib shows that it can help patients avoid disease progression for a certain period of time. Specific PFS data may vary by study and patient population, but in general, platinib improves progression-free survival and quality of life.

According to clinical trial results, the median progression-free survival (PFS) of patients with RET-mutated non-small cell lung cancer treated with platinib was 22.4 months, which was significantly longer than that of the control group. In addition, the overall response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS) of patients with RET-mutant thyroid cancer treated with platinib was 73.2%, 73.2%, 93.3%, and 20.6 months.

These data show that Platinib has significant clinical effects in the treatment ofRET-mutated non-small cell lung cancer and thyroid cancer, and can significantly extend the progression-free survival of patients and improve their quality of life. However, these data are only available for patient populations in clinical trials and have certain limitations, such as small sample sizes and short follow-up periods. Therefore, in practical applications, patients should undergo individualized treatment according to the doctor's advice and guidance, and closely monitor treatment effects and adverse reactions.